A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis

Atsushi Kuno, Yuzuru Ikehara, Yasuhito Tanaka, Kiyoaki Ito, Atsushi Matsuda, Satoru Sekiya, Shuhei Hige, Michiie Sakamoto, Masayoshi Kage, Masashi Mizokami, Hisashi Narimatsu

Research output: Contribution to journalArticlepeer-review

192 Citations (Scopus)

Abstract

Although liver fibrosis reflects disease severity in chronic hepatitis patients, there has been no simple and accurate system to evaluate the therapeutic effect based on fibrosis. We developed a glycan-based immunoassay, FastLec-Hepa, to fill this unmet need. FastLec-Hepa automatically detects unique fibrosis-related glyco-alteration in serum hyperglycosylated Mac-2 binding protein within 20 min. The serum FastLec-Hepa counts increased with advancing fibrosis and illustrated significant differences in medians between all fibrosis stages. FastLec-Hepa is sufficiently sensitive and quantitative to evaluate the effects of PEG-interferon-α/ribavirin therapy in a short post-therapeutic interval. The obtained fibrosis progression is equivalent to-0.30 stages/year in patients with sustained virological response, and 0.01 stages/year in relapse/nonresponders. Furthermore, long-term follow-up of the severely affected patients found hepatocellular carcinoma developed in patients after therapy whose FastLec-Hepa counts remained above a designated cutoff value. FastLec-Hepa is the only assay currently available for clinically beneficial therapy evaluation through quantitation of disease severity.

Original languageEnglish
Article number1065
JournalScientific reports
Volume3
DOIs
Publication statusPublished - 2013

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis'. Together they form a unique fingerprint.

Cite this